Study of Adult Patients Residing in Argentina Diagnosed With Type 2 Diabetes Treated With a New Formulation of Semaglutide, Both Oral and Subcutaneous, in a Real-world Setting at 3 Months, 6 Months, and 1 Year of Follow-up, Quantifying the Reduction in Glycated Hemoglobin
Clinical trial NCT07621419 · RECRUITING
Trial details
- NCT number
- NCT07621419
- Sponsor
- Hospital Italiano de Buenos Aires
- Status
- RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2025-08-04
- Primary completion
- 2027-12-31
- Enrollment
- 145
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.